{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:10:54Z","timestamp":1759335054407,"version":"build-2065373602"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371413","82171399"],"award-info":[{"award-number":["82371413","82171399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10072-025-08328-y","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T23:11:34Z","timestamp":1750893094000},"page":"5327-5339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating inflammatory proteins as pathogenic mediators and potential therapeutic targets in myasthenia gravis"],"prefix":"10.1007","volume":"46","author":[{"given":"Kangzhi","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chudai","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhen","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanzhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-2544","authenticated-orcid":false,"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"1","key":"8328_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"8328_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","volume":"21","author":"AR Punga","year":"2022","unstructured":"Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A (2022) Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol 21(2):176\u2013188. https:\/\/doi.org\/10.1016\/S1474-4422(21)00297-0.","journal-title":"Lancet Neurol"},{"issue":"5\u20136","key":"8328_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/08916930903555943","volume":"43","author":"AM Gomez","year":"2010","unstructured":"Gomez AM, Van Den Broeck J, Vrolix K, Janssen SP, Lemmens MAM, Van Der Esch E, Duimel H, Frederik P, Molenaar PC, Mart\u00ednez-Mart\u00ednez P, De Baets MH, Losen M (2010) Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 43(5\u20136):353\u2013370. https:\/\/doi.org\/10.3109\/08916930903555943.","journal-title":"Autoimmunity"},{"key":"8328_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","volume":"52","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S, Le Panse R (2014) Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 52:90\u2013100. https:\/\/doi.org\/10.1016\/j.jaut.2013.12.011.","journal-title":"J Autoimmun"},{"key":"8328_CR5","doi-asserted-by":"publisher","first-page":"1083218","DOI":"10.3389\/fimmu.2023.1083218","volume":"14","author":"J Verdier","year":"2023","unstructured":"Verdier J, Fayet O-M, Hemery E, Truffault F, Pinz\u00f3n N, Demeret S, Behin A, Fadel E, Guihaire J, Corneau A, Blanc C, Berrih-Aknin S, Le Panse R (2023) Single-cell mass cytometry on peripheral cells in myasthenia gravis identifies dysregulation of innate immune cells. Front Immunol 14:1083218. https:\/\/doi.org\/10.3389\/fimmu.2023.1083218.","journal-title":"Front Immunol"},{"issue":"6","key":"8328_CR6","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00401-021-02299-y","volume":"141","author":"F Ingelfinger","year":"2021","unstructured":"Ingelfinger F, Krishnarajah S, Kramer M, Utz SG, Galli E, Lutz M, Zwicky P, Akarca AU, Jurado NP, Ulutekin C, Bamert D, Widmer CC, Piccoli L, Sallusto F, N\u00fa\u00f1ez NG, Marafioti T, Schneiter D, Opitz I, Lanzavecchia A, Jung HH, De Feo D, Mundt S, Schreiner B, Becher B (2021) Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. Acta Neuropathol 141(6):901\u2013915. https:\/\/doi.org\/10.1007\/s00401-021-02299-y.","journal-title":"Acta Neuropathol"},{"key":"8328_CR7","doi-asserted-by":"publisher","first-page":"109184","DOI":"10.1016\/j.clim.2022.109184","volume":"245","author":"R Fan","year":"2022","unstructured":"Fan R, Que W, Liu Z, Zheng W, Guo X, Liu L, Xiao F (2022) Single-cell mapping reveals dysregulation of immune cell populations and VISTA\u2009+\u2009monocytes in myasthenia gravis. Clin Immunol (Orlando Fla) 245:109184. https:\/\/doi.org\/10.1016\/j.clim.2022.109184.","journal-title":"Clin Immunol (Orlando Fla)"},{"issue":"1","key":"8328_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41421-021-00314-w","volume":"7","author":"W Jin","year":"2021","unstructured":"Jin W, Yang Q, Peng Y, Yan C, Li Y, Luo Z, Xiao B, Xu L, Yang H (2021) Single-cell RNA-Seq reveals transcriptional heterogeneity and immune subtypes associated with disease activity in human myasthenia gravis. Cell Discov 7(1):85. https:\/\/doi.org\/10.1038\/s41421-021-00314-w.","journal-title":"Cell Discov"},{"key":"8328_CR9","doi-asserted-by":"publisher","first-page":"25886","DOI":"10.1038\/srep25886","volume":"6","author":"A Uzawa","year":"2016","unstructured":"Uzawa A, Kanai T, Kawaguchi N, Oda F, Himuro K, Kuwabara S (2016) Changes in inflammatory cytokine networks in myasthenia gravis. Sci Rep 6:25886. https:\/\/doi.org\/10.1038\/srep25886.","journal-title":"Sci Rep"},{"issue":"2","key":"8328_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/cei.12272","volume":"176","author":"A Uzawa","year":"2014","unstructured":"Uzawa A, Kawaguchi N, Himuro K, Kanai T, Kuwabara S (2014) Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clin Exp Immunol 176(2):232\u2013237. https:\/\/doi.org\/10.1111\/cei.12272.","journal-title":"Clin Exp Immunol"},{"key":"8328_CR11","doi-asserted-by":"publisher","first-page":"578205","DOI":"10.1016\/j.jneuroim.2023.578205","volume":"384","author":"M Yasuda","year":"2023","unstructured":"Yasuda M, Uzawa A, Ozawa Y, Kojima Y, Onishi Y, Akamine H, Kuwabara S (2023) Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies. J Neuroimmunol 384:578205. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578205.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"8328_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12865-022-00501-8","volume":"23","author":"X Huan","year":"2022","unstructured":"Huan X, Zhao R, Song J, Zhong H, Su M, Yan C, Wang Y, Chen S, Zhou Z, Lu J, Xi J, Luo S, Zhao C (2022) Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis. BMC Immunol 23(1):26. https:\/\/doi.org\/10.1186\/s12865-022-00501-8.","journal-title":"BMC Immunol"},{"issue":"11","key":"8328_CR13","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1681\/ASN.2016010098","volume":"27","author":"P Sekula","year":"2016","unstructured":"Sekula P, Del Greco MF, Pattaro C, K\u00f6ttgen A (2016) Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol 27(11):3253\u20133265. https:\/\/doi.org\/10.1681\/ASN.2016010098.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"8328_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/gepi.22506","volume":"47","author":"A Gkatzionis","year":"2023","unstructured":"Gkatzionis A, Burgess S, Newcombe PJ (2023) Statistical methods for cis-Mendelian randomization with two-sample summary-level data. Genet Epidemiol 47(1):3\u201325. https:\/\/doi.org\/10.1002\/gepi.22506.","journal-title":"Genet Epidemiol"},{"key":"8328_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/ITT.S377056","volume":"12","author":"SS Nair","year":"2023","unstructured":"Nair SS, Jacob S (2023) Novel immunotherapies for myasthenia gravis. ImmunoTargets Therapy 12:25\u201345. https:\/\/doi.org\/10.2147\/ITT.S377056.","journal-title":"ImmunoTargets Therapy"},{"issue":"7","key":"8328_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10654-015-0011-z","volume":"30","author":"S Burgess","year":"2015","unstructured":"Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG (2015) Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol 30(7):543\u2013552. https:\/\/doi.org\/10.1007\/s10654-015-0011-z.","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"8328_CR17","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41590-023-01588-w","volume":"24","author":"JH Zhao","year":"2023","unstructured":"Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman \u00c5K, Kalnapenkis A, Enroth S, Cozzetto D, Digby-Bell J, Marten J, Folkersen L, Herder C, Jonsson L, Bergen SE, Gieger C, Needham EJ, Surendran P, Paul DS, Polasek O, Thorand B, Grallert H, Roden M, V\u00f5sa U, Esko T, Hayward C, Johansson \u00c5, Gyllensten U, Powell N, Hansson O, Mattsson-Carlgren N, Joshi PK, Danesh J, Padyukov L, Klareskog L, Land\u00e9n M, Wilson JF, Siegbahn A, Wallentin L, M\u00e4larstig A, Butterworth AS, Peters JE (2023) Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol 24(9):1540\u20131551. https:\/\/doi.org\/10.1038\/s41590-023-01588-w.","journal-title":"Nat Immunol"},{"issue":"3","key":"8328_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/0962280210394459","volume":"21","author":"TM Palmer","year":"2012","unstructured":"Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, Davey Smith G, Sterne JA (2012) Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 21(3):223\u2013242. https:\/\/doi.org\/10.1177\/0962280210394459.","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"8328_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/gepi.21998","volume":"40","author":"S Burgess","year":"2016","unstructured":"Burgess S, Davies NM, Thompson SG (2016) Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol 40(7):597\u2013608. https:\/\/doi.org\/10.1002\/gepi.21998.","journal-title":"Genet Epidemiol"},{"issue":"5","key":"8328_CR20","doi-asserted-by":"publisher","first-page":"e2108672119","DOI":"10.1073\/pnas.2108672119","volume":"119","author":"R Chia","year":"2022","unstructured":"Chia R, Saez-Atienzar S, Murphy N, Chi\u00f2 A, Blauwendraat C, Roda RH, Tienari PJ, Kaminski HJ, Ricciardi R, Guida M, De Rosa A, Petrucci L, Evoli A, Provenzano C, Drachman DB, Traynor BJ (2022) Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proc Natl Acad Sci USA 119(5):e2108672119. https:\/\/doi.org\/10.1073\/pnas.2108672119.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"8328_CR21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","volume":"72","author":"AE Renton","year":"2015","unstructured":"Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, Chi\u00f2 A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ (2015) A genome-wide association study of myasthenia gravis. JAMA Neurol 72(4):396\u2013404. https:\/\/doi.org\/10.1001\/jamaneurol.2014.4103.","journal-title":"JAMA Neurol"},{"issue":"3","key":"8328_CR22","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1214\/19-AOS1866","volume":"48","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, Wang J, Hemani G, Bowden J, Small DS (2020) Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. Annals Stat 48(3):1742\u20131769. https:\/\/doi.org\/10.1214\/19-AOS1866.","journal-title":"Annals Stat"},{"issue":"5","key":"8328_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, Chen C-Y, Neale B, Do R (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 50(5):693\u2013698. https:\/\/doi.org\/10.1038\/s41588-018-0099-7.","journal-title":"Nat Genet"},{"issue":"11","key":"8328_CR24","doi-asserted-by":"publisher","first-page":"e1007081","DOI":"10.1371\/journal.pgen.1007081","volume":"13","author":"G Hemani","year":"2017","unstructured":"Hemani G, Tilling K, Davey Smith G (2017) Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet 13(11):e1007081. https:\/\/doi.org\/10.1371\/journal.pgen.1007081.","journal-title":"PLoS Genet"},{"issue":"8","key":"8328_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jclinepi.2014.03.012","volume":"67","author":"ME Glickman","year":"2014","unstructured":"Glickman ME, Rao SR, Schultz MR (2014) False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. J Clin Epidemiol 67(8):850\u2013857. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.03.012.","journal-title":"J Clin Epidemiol"},{"issue":"23","key":"8328_CR26","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH (2020) Cytokine storm. N Engl J Med 383(23):2255\u20132273. https:\/\/doi.org\/10.1056\/NEJMra2026131.","journal-title":"N Engl J Med"},{"issue":"3","key":"8328_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41577-023-00933-2","volume":"24","author":"A Cheng","year":"2024","unstructured":"Cheng A, Holland SM (2024) Anti-cytokine autoantibodies: mechanistic insights and disease associations. Nat Rev Immunol 24(3):161\u2013177. https:\/\/doi.org\/10.1038\/s41577-023-00933-2.","journal-title":"Nat Rev Immunol"},{"key":"8328_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-pathmechdis-030121-041528","volume":"17","author":"JE Rood","year":"2022","unstructured":"Rood JE, Behrens EM (2022) Inherited autoinflammatory syndromes. Annu Rev Pathol 17:227\u2013249. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-030121-041528.","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"8328_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/mus.22070","volume":"44","author":"JC Roche","year":"2011","unstructured":"Roche JC, Capablo JL, Larrad L, Gervas-Arruga J, Ara JR, S\u00e1nchez A, Alarcia R (2011) Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve 44(2):278\u2013280. https:\/\/doi.org\/10.1002\/mus.22070.","journal-title":"Muscle Nerve"},{"issue":"1","key":"8328_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/sji.12057","volume":"78","author":"S Zheng","year":"2013","unstructured":"Zheng S, Dou C, Xin N, Wang J, Wang J, Li P, Fu L, Shen X, Cui G, Dong R, Lu J, Zhang Y (2013) Expression of interleukin-22 in myasthenia gravis. Scand J Immunol 78(1):98\u2013107. https:\/\/doi.org\/10.1111\/sji.12057.","journal-title":"Scand J Immunol"},{"issue":"6","key":"8328_CR31","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/mus.25162","volume":"54","author":"SY Kang","year":"2016","unstructured":"Kang SY, Kang CH, Lee KH (2016) B-cell-activating factor is elevated in serum of patients with myasthenia gravis. Muscle Nerve 54(6):1030\u20131033. https:\/\/doi.org\/10.1002\/mus.25162.","journal-title":"Muscle Nerve"},{"issue":"1","key":"8328_CR32","doi-asserted-by":"publisher","first-page":"e23745","DOI":"10.1016\/j.heliyon.2023.e23745","volume":"10","author":"SL Wei","year":"2024","unstructured":"Wei SL, Yang CL, Si WY, Dong J, Zhao XL, Zhang P, Li H, Wang CC, Zhang M, Li XL, Duan RS (2024) Altered serum levels of cytokines in patients with myasthenia gravis. Heliyon 10(1):e23745. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23745.","journal-title":"Heliyon"},{"issue":"8","key":"8328_CR33","doi-asserted-by":"publisher","first-page":"110564","DOI":"10.1016\/j.isci.2024.110564","volume":"27","author":"AK Bhandage","year":"2024","unstructured":"Bhandage AK, Kenina V, Huang YF, Roddate M, Kauke G, Grosmane A, \u017dukova V, Eriksson N, Gabrysch K, Punga T, Punga AR (2024) Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls. iScience 27(8):110564. https:\/\/doi.org\/10.1016\/j.isci.2024.110564.","journal-title":"iScience"},{"key":"8328_CR34","doi-asserted-by":"publisher","first-page":"106130","DOI":"10.1016\/j.intimp.2019.106130","volume":"80","author":"Y Hu","year":"2020","unstructured":"Hu Y, Wang J, Rao J, Xu X, Cheng Y, Yan L, Wu Y, Wu N, Wu X (2020) Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis. Int Immunopharmacol 80:106130. https:\/\/doi.org\/10.1016\/j.intimp.2019.106130.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"8328_CR35","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.4049\/jimmunol.1901176","volume":"204","author":"Z Liu","year":"2020","unstructured":"Liu Z, Zhu L, Lu Z, Chen H, Fan L, Xue Q, Shi J, Li M, Li H, Gong J, Shi J, Wang T, Jiang ML, Cao R, Meng H, Wang C, Xu Y, Zhang CJ (2020) IL-37 represses the autoimmunity in myasthenia gravis via directly targeting follicular Th and B cells. J Immunol 204(7):1736\u20131745. https:\/\/doi.org\/10.4049\/jimmunol.1901176.","journal-title":"J Immunol"},{"key":"8328_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jaut.2013.12.016","volume":"52","author":"P Cufi","year":"2014","unstructured":"Cufi P, Dragin N, Ruhlmann N, Weiss JM, Fadel E, Serraf A, Berrih-Aknin S, Le Panse R (2014) Central role of interferon-beta in thymic events leading to myasthenia gravis. J Autoimmun 52:44\u201352. https:\/\/doi.org\/10.1016\/j.jaut.2013.12.016.","journal-title":"J Autoimmun"},{"issue":"1","key":"8328_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/cnd.0000000000000446","volume":"25","author":"MN Bouchtout","year":"2023","unstructured":"Bouchtout MN, Me\u00e7abih F, Boukadir C, Attal E, Daoudi S, Benkortbi H, Touil-Boukoffa C, Raache R, Attal N (2023) Cytokines single nucleotide polymorphisms (SNPs) association with myasthenia gravis (MG) in Algerian patients: a case-control study on A small group. J Clin Neuromuscul Dis 25(1):18\u201326. https:\/\/doi.org\/10.1097\/cnd.0000000000000446.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"9","key":"8328_CR38","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","volume":"12","author":"A Marx","year":"2013","unstructured":"Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Str\u00f6bel P (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12(9):875\u2013884. https:\/\/doi.org\/10.1016\/j.autrev.2013.03.007.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"8328_CR39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.26169","volume":"90","author":"L Handunnetthi","year":"2021","unstructured":"Handunnetthi L, Knezevic B, Kasela S, Burnham KL, Milani L, Irani SR, Fang H, Knight JC (2021) Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease. Ann Neurol 90(3):455\u2013463. https:\/\/doi.org\/10.1002\/ana.26169.","journal-title":"Ann Neurol"},{"issue":"1","key":"8328_CR40","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2119\/molmed.2015.00232","volume":"21","author":"MF Seldin","year":"2016","unstructured":"Seldin MF, Alkhairy OK, Lee AT, Lamb JA, Sussman J, Pirskanen-Matell R, Piehl F, Verschuuren J, Kostera-Pruszczyk A, Szczudlik P, McKee D, Maniaol AH, Harbo HF, Lie BA, Melms A, Garchon HJ, Willcox N, Gregersen PK, Hammarstrom L (2016) Genome-wide association study of late-onset myasthenia gravis: confirmation of TNFRSF11A and identification of ZBTB10 and three distinct HLA associations. Mol Med 21(1):769\u2013781. https:\/\/doi.org\/10.2119\/molmed.2015.00232.","journal-title":"Mol Med"},{"issue":"1","key":"8328_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40246-024-00607-7","volume":"18","author":"Y Ouyang","year":"2024","unstructured":"Ouyang Y, Chen Y, Chen K, Tang Z, Shi G, Qu C, Zhang K, Yang H (2024) Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis. Hum Genomics 18(1):43. https:\/\/doi.org\/10.1186\/s40246-024-00607-7.","journal-title":"Hum Genomics"},{"key":"8328_CR42","doi-asserted-by":"publisher","first-page":"15395","DOI":"10.1038\/ncomms15395","volume":"8","author":"D Sidler","year":"2017","unstructured":"Sidler D, Wu P, Herro R, Claus M, Wolf D, Kawakami Y, Kawakami T, Burkly L, Croft M (2017) TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis. Nat Commun 8:15395. https:\/\/doi.org\/10.1038\/ncomms15395.","journal-title":"Nat Commun"},{"issue":"65","key":"8328_CR43","doi-asserted-by":"publisher","first-page":"eabi8823","DOI":"10.1126\/sciimmunol.abi8823","volume":"6","author":"RK Gupta","year":"2021","unstructured":"Gupta RK, Gracias DT, Figueroa DS, Miki H, Miller J, Fung K, Ay F, Burkly L, Croft M (2021) TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy. Sci Immunol 6(65):eabi8823. https:\/\/doi.org\/10.1126\/sciimmunol.abi8823.","journal-title":"Sci Immunol"},{"issue":"1","key":"8328_CR44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12916-024-03314-1","volume":"22","author":"QQ Duan","year":"2024","unstructured":"Duan QQ, Wang H, Su WM, Gu XJ, Shen XF, Jiang Z, Ren YL, Cao B, Li GB, Wang Y, Chen YP (2024) TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro. BMC Med 22(1):96. https:\/\/doi.org\/10.1186\/s12916-024-03314-1.","journal-title":"BMC Med"},{"issue":"10","key":"8328_CR45","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/circulationaha.119.040180","volume":"140","author":"M Chong","year":"2019","unstructured":"Chong M, Sjaarda J, Pigeyre M, Mohammadi-Shemirani P, Lali R, Shoamanesh A, Gerstein HC, Par\u00e9 G (2019) Novel drug targets for ischemic stroke identified through Mendelian randomization analysis of the blood proteome. Circulation 140(10):819\u2013830. https:\/\/doi.org\/10.1161\/circulationaha.119.040180.","journal-title":"Circulation"},{"issue":"8","key":"8328_CR46","doi-asserted-by":"publisher","first-page":"e16322","DOI":"10.1111\/ene.16322","volume":"31","author":"J Yin","year":"2024","unstructured":"Yin J, Zhao M, Xu X, Zhang M, Xu Z, Li Z, Qin X, Li Z, Zhao C, Zhou H, Ma Y, Cao W, Wang G, Lin Y, Zhang J, Zhang X, Cai H, Qian W, Wang Y, Zhang X, Liu G, Wang J, Qiu W, Min L, Li J, Deng H, Chu L, Zhang Y, Fang J (2024) A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. Eur J Neurol 31(8):e16322. https:\/\/doi.org\/10.1111\/ene.16322.","journal-title":"Eur J Neurol"},{"issue":"16","key":"8328_CR47","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/wnl.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, Zvartau-Hind M, Bril V (2018) Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology 90(16):e1425\u2013e1434. https:\/\/doi.org\/10.1212\/wnl.0000000000005323.","journal-title":"Neurology"},{"issue":"1","key":"8328_CR48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/bcp.12914","volume":"82","author":"GR Galluppi","year":"2016","unstructured":"Galluppi GR, Wisniacki N, Stebbins C (2016) Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody. Br J Clin Pharmacol 82(1):118\u2013128. https:\/\/doi.org\/10.1111\/bcp.12914.","journal-title":"Br J Clin Pharmacol"},{"key":"8328_CR49","doi-asserted-by":"publisher","first-page":"648182","DOI":"10.3389\/fimmu.2021.648182","volume":"12","author":"L Sun","year":"2021","unstructured":"Sun L, Gang X, Li Z, Zhao X, Zhou T, Zhang S, Wang G (2021) Advances in understanding the roles of CD244 (SLAMF4) in immune regulation and associated diseases. Front Immunol 12:648182. https:\/\/doi.org\/10.3389\/fimmu.2021.648182.","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"8328_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jneuroim.2006.05.028","volume":"179","author":"S Nguyen","year":"2006","unstructured":"Nguyen S, Morel V, Le Garff-Tavernier M, Bolgert F, Leblond V, Debr\u00e9 P, Vieillard V (2006) Persistence of CD16+\/CD56-\/2B4\u2009+\u2009natural killer cells: a highly dysfunctional NK subset expanded in ocular myasthenia gravis. J Neuroimmunol 179(1\u20132):117\u2013125. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.05.028.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"8328_CR51","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1182\/blood-2005-06-2383","volume":"108","author":"A Meraouna","year":"2006","unstructured":"Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tallaksen C, Berrih-Aknin S (2006) The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108(2):432\u2013440. https:\/\/doi.org\/10.1182\/blood-2005-06-2383.","journal-title":"Blood"},{"key":"8328_CR52","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clim.2015.12.009","volume":"164","author":"XF Liu","year":"2016","unstructured":"Liu XF, Wang RQ, Hu B, Luo MC, Zeng QM, Zhou H, Huang K, Dong XH, Luo YB, Luo ZH, Yang H (2016) MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10. Clin Immunol 164:106\u2013113. https:\/\/doi.org\/10.1016\/j.clim.2015.12.009.","journal-title":"Clin Immunol"},{"issue":"8","key":"8328_CR53","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s10238-023-01152-8","volume":"23","author":"CL Dai","year":"2023","unstructured":"Dai CL, Yang HX, Liu QP, Rahman K, Zhang H (2023) CXCL6: a potential therapeutic target for inflammation and cancer. Clin Exp Med 23(8):4413\u20134427. https:\/\/doi.org\/10.1007\/s10238-023-01152-8.","journal-title":"Clin Exp Med"},{"issue":"2","key":"8328_CR54","doi-asserted-by":"publisher","first-page":"R48","DOI":"10.1186\/ar3761","volume":"14","author":"F Suzuki","year":"2012","unstructured":"Suzuki F, Kubota T, Miyazaki Y, Ishikawa K, Ebisawa M, Hirohata S, Ogura T, Mizusawa H, Imai T, Miyasaka N, Nanki T (2012) Serum level of soluble CX3CL1\/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity. Arthritis Res Ther 14(2):R48. https:\/\/doi.org\/10.1186\/ar3761.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"8328_CR55","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3988\/jcn.2022.0265","volume":"19","author":"JW Seok","year":"2023","unstructured":"Seok JW, Lee J, Kim M, Kim MJ, Shin HY, Kim SW (2023) Plasma myokine profiles in patients with AChR- and MuSK-Ab-Positive myasthenia gravis. J Clin Neurol 19(5):469\u2013477. https:\/\/doi.org\/10.3988\/jcn.2022.0265.","journal-title":"J Clin Neurol"},{"issue":"4","key":"8328_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/art.41555","volume":"73","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, Imai T (2021) Efficacy and safety of E6011, an anti-fractalkine monoclonal antibody, in patients with active rheumatoid arthritis with inadequate response to methotrexate: results of a randomized, double-blind, placebo-controlled phase II study. Arthritis Rheumatol 73(4):587\u2013595. https:\/\/doi.org\/10.1002\/art.41555.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"8328_CR57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/ijms22010136","volume":"22","author":"S Stanga","year":"2020","unstructured":"Stanga S, Boido M, Kienlen-Campard P (2020) How to build and to protect the neuromuscular junction: the role of the glial cell line-derived neurotrophic factor. Int J Mol Sci 22(1):136. https:\/\/doi.org\/10.3390\/ijms22010136.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"8328_CR58","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1084\/jem.170.3.827","volume":"170","author":"M Kobayashi","year":"1989","unstructured":"Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170(3):827\u2013845. https:\/\/doi.org\/10.1084\/jem.170.3.827.","journal-title":"J Exp Med"},{"issue":"8","key":"8328_CR59","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/(sici)1521-4141(199808)28:08<2487::Aid-immu2487>3.0.Co;2-y","volume":"28","author":"L Moiola","year":"1998","unstructured":"Moiola L, Galbiati F, Martino G, Amadio S, Brambilla E, Comi G, Vincent A, Grimaldi LM, Adorini L (1998) IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur J Immunol 28(8):2487\u20132497. https:\/\/doi.org\/10.1002\/(sici)1521-4141(199808)28:08%3C;2487::Aid-immu2487%3E;3.0.Co;2-y.","journal-title":"Eur J Immunol"},{"issue":"1\u20132","key":"8328_CR60","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jneuroim.2006.02.012","volume":"175","author":"H Yoshikawa","year":"2006","unstructured":"Yoshikawa H, Sato K, Edahiro S, Furukawa Y, Maruta T, Iwasa K, Watanabe H, Takaoka S, Suzuki Y, Takamori M, Yamada M (2006) Elevation of IL-12 p40 and its antibody in myasthenia gravis with thymoma. J Neuroimmunol 175(1\u20132):169\u2013175. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.02.012.","journal-title":"J Neuroimmunol"},{"issue":"4","key":"8328_CR61","doi-asserted-by":"publisher","first-page":"e0123546","DOI":"10.1371\/journal.pone.0123546","volume":"10","author":"V Yilmaz","year":"2015","unstructured":"Yilmaz V, Oflazer P, Aysal F, Durmus H, Poulas K, Yentur SP, Gulsen-Parman Y, Tzartos S, Marx A, Tuzun E, Deymeer F, Saruhan-Direskeneli G (2015) Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK. PLoS ONE 10(4):e0123546. https:\/\/doi.org\/10.1371\/journal.pone.0123546.","journal-title":"PLoS ONE"},{"issue":"9","key":"8328_CR62","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/eji.1830230923","volume":"23","author":"F Mattner","year":"1993","unstructured":"Mattner F, Fischer S, Guckes S, Jin S, Kaulen H, Schmitt E, R\u00fcde E, Germann T (1993) The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol 23(9):2202\u20132208. https:\/\/doi.org\/10.1002\/eji.1830230923.","journal-title":"Eur J Immunol"},{"issue":"3","key":"8328_CR63","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.nmd.2020.01.001","volume":"30","author":"G Nicocia","year":"2020","unstructured":"Nicocia G, Bonanno C, Lupica A, Toscano A, Rodolico C (2020) Myasthenia gravis after etanercept and ustekinumab treatment for psoriatic arthritis: a case report. Neuromuscul Disord 30(3):246\u2013249. https:\/\/doi.org\/10.1016\/j.nmd.2020.01.001.","journal-title":"Neuromuscul Disord"},{"key":"8328_CR64","doi-asserted-by":"publisher","first-page":"108191","DOI":"10.1016\/j.pharmthera.2022.108191","volume":"239","author":"JM Thomas","year":"2022","unstructured":"Thomas JM, Huuskes BM, Sobey CG, Drummond GR, Vinh A (2022) The IL-18\/IL-18R1 signalling axis: diagnostic and therapeutic potential in hypertension and chronic kidney disease. Pharmacol Ther 239:108191. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108191.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"8328_CR65","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/ar3295","volume":"13","author":"S Takei","year":"2011","unstructured":"Takei S, Hoshino T, Matsunaga K, Sakazaki Y, Sawada M, Oda H, Takenaka S, Imaoka H, Kinoshita T, Honda S, Ida H, Fukuda TA, Aizawa H (2011) Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. Arthritis Res Ther 13(2):R52. https:\/\/doi.org\/10.1186\/ar3295.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"8328_CR66","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay C, Fautrel B, Rech J, Spertini F, Feist E, K\u00f6tter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann Rheum Dis 77(6):840\u2013847. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212608.","journal-title":"Ann Rheum Dis"},{"key":"8328_CR67","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jocn.2023.11.013","volume":"119","author":"B GomezMancilla","year":"2024","unstructured":"GomezMancilla B, Meriggioli MN, Genge A, Roubenoff R, Espi\u00e9 P, Dupuy C, Hartmann N, Pezous N, Kinhikar A, Tichy M, Dionne A, Vissing J, Andersen H, Schoser B, Meisel A, Jordan B, Devlikamova F, Poverennova I, Stuchevskaya F, Lin TS, Rush JS, Gergely P (2024) Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: a phase 2 randomized study. J Clin Neurosci 119:76\u201384. https:\/\/doi.org\/10.1016\/j.jocn.2023.11.013.","journal-title":"J Clin Neurosci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08328-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08328-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08328-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T03:10:54Z","timestamp":1759288254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08328-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["8328"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08328-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the publicly available nature of the GWAS data used in this study, ethical approval has been already conducted in respective original articles. All procedures were performed in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}